Cargando…
Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strateg...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130674/ https://www.ncbi.nlm.nih.gov/pubmed/34017336 http://dx.doi.org/10.3389/fimmu.2021.660037 |
_version_ | 1783694568928051200 |
---|---|
author | Ehlers, Anna M. den Hartog Jager, Constance F. Kardol-Hoefnagel, Tineke Katsburg, Miriam M.D. Knulst, André C. Otten, Henny G. |
author_facet | Ehlers, Anna M. den Hartog Jager, Constance F. Kardol-Hoefnagel, Tineke Katsburg, Miriam M.D. Knulst, André C. Otten, Henny G. |
author_sort | Ehlers, Anna M. |
collection | PubMed |
description | Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strategies to generate human mAbs from peripheral blood have been described and used in several studies including single cell sequencing of antigen-binding B cells and the establishment of antigen-specific monoclonal Epstein-Barr Virus (EBV) immortalized lymphoblastoid cell lines (LCLs). However, direct comparisons of these two strategies are scarce. Hence, we sought to set up these two strategies in our laboratory using peanut 2S albumins (allergens) and the autoantigen anti-Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2, alternatively ‘ARHGDIB’) as antigen targets to directly compare these strategies regarding costs, time expenditure, recovery, throughput and complexity. Regarding single cell sequencing, up to 50% of corresponding V(D)J gene transcripts were successfully amplified of which 54% were successfully cloned into expression vectors used for heterologous expression. Seventy-five percent of heterologously expressed mAbs showed specific binding to peanut 2S albumins resulting in an overall recovery of 20.3%, which may be increased to around 29% by ordering gene sequences commercially for antibody cloning. In comparison, the establishment of monoclonal EBV-LCLs showed a lower overall recovery of around 17.6%. Heterologous expression of a mAb carrying the same variable region as its native counterpart showed comparable concentration-dependent binding abilities. By directly comparing those two strategies, single cell sequencing allows a broad examination of antigen-binding mAbs in a moderate-throughput manner, while the establishment of monoclonal EBV-LCLs is a powerful tool to select a small number of highly reactive mAbs restricted to certain B cell subpopulations. Overall, both strategies, initially set-up for peanut 2S albumins, are suitable to obtain human mAbs and they are easily transferrable to other target antigens as shown for ARHGDIB. |
format | Online Article Text |
id | pubmed-8130674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81306742021-05-19 Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? Ehlers, Anna M. den Hartog Jager, Constance F. Kardol-Hoefnagel, Tineke Katsburg, Miriam M.D. Knulst, André C. Otten, Henny G. Front Immunol Immunology Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strategies to generate human mAbs from peripheral blood have been described and used in several studies including single cell sequencing of antigen-binding B cells and the establishment of antigen-specific monoclonal Epstein-Barr Virus (EBV) immortalized lymphoblastoid cell lines (LCLs). However, direct comparisons of these two strategies are scarce. Hence, we sought to set up these two strategies in our laboratory using peanut 2S albumins (allergens) and the autoantigen anti-Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2, alternatively ‘ARHGDIB’) as antigen targets to directly compare these strategies regarding costs, time expenditure, recovery, throughput and complexity. Regarding single cell sequencing, up to 50% of corresponding V(D)J gene transcripts were successfully amplified of which 54% were successfully cloned into expression vectors used for heterologous expression. Seventy-five percent of heterologously expressed mAbs showed specific binding to peanut 2S albumins resulting in an overall recovery of 20.3%, which may be increased to around 29% by ordering gene sequences commercially for antibody cloning. In comparison, the establishment of monoclonal EBV-LCLs showed a lower overall recovery of around 17.6%. Heterologous expression of a mAb carrying the same variable region as its native counterpart showed comparable concentration-dependent binding abilities. By directly comparing those two strategies, single cell sequencing allows a broad examination of antigen-binding mAbs in a moderate-throughput manner, while the establishment of monoclonal EBV-LCLs is a powerful tool to select a small number of highly reactive mAbs restricted to certain B cell subpopulations. Overall, both strategies, initially set-up for peanut 2S albumins, are suitable to obtain human mAbs and they are easily transferrable to other target antigens as shown for ARHGDIB. Frontiers Media S.A. 2021-05-04 /pmc/articles/PMC8130674/ /pubmed/34017336 http://dx.doi.org/10.3389/fimmu.2021.660037 Text en Copyright © 2021 Ehlers, den Hartog Jager, Kardol-Hoefnagel, Katsburg, Knulst and Otten https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ehlers, Anna M. den Hartog Jager, Constance F. Kardol-Hoefnagel, Tineke Katsburg, Miriam M.D. Knulst, André C. Otten, Henny G. Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? |
title | Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? |
title_full | Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? |
title_fullStr | Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? |
title_full_unstemmed | Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? |
title_short | Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? |
title_sort | comparison of two strategies to generate antigen-specific human monoclonal antibodies: which method to choose for which purpose? |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130674/ https://www.ncbi.nlm.nih.gov/pubmed/34017336 http://dx.doi.org/10.3389/fimmu.2021.660037 |
work_keys_str_mv | AT ehlersannam comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose AT denhartogjagerconstancef comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose AT kardolhoefnageltineke comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose AT katsburgmiriammd comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose AT knulstandrec comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose AT ottenhennyg comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose |